A rteriovenous malformation (AVM) is the most common cause of intracerebral hemorrhage (ICH) in children. 4, 5 The annual risk of hemorrhage in pediatric AVM is approximately 3.2% per year, 17 with 5%-10% risk of death and up to 50% risk of neurological morbidity. 1, 12, 15, 17 Early and complete treatment of these malformations in children is therefore important. Current treatment options include microsurgery, endovascular embolization, radiosurgery, or combined therapy.
Despite the need for accurate and timely diagnosis of recurrence, the optimal follow-up strategy in children has not been demonstrated. Some studies recommend imaging 6-12 months after a negative postoperative digital subtraction angiogram to rule out recurrent or residual AVM. 13, 16, 20, 29 With reported cases of recurrence occurring 3 months to 16 years after primary treatment, 1, 2, 13, 16, 26, 29 a more extended imaging protocol is likely necessary to capture recurrence and prevent associated morbidity. Follow-up imaging, however, carries additional risk, cost, and time. The appropriate follow-up modality and timing are therefore subjects of debate, particularly in light of concerns regarding radiation exposure and general anesthesia in children. 7, 22, 30 We present our experience with surveillance for AVM recurrence, associated risk factors, and clinical outcome, while considering the implications of these findings for follow-up protocols after treatment.
methods
This retrospective study was approved by the Weill Cornell Medical College Institutional Review Board. Patients younger than 18 years of age diagnosed with AVM by digital subtraction angiography (DSA) from 1998 to 2012 at the primary institution were identified, and those with complete nidus obliteration after treatment with more than 12 months of follow-up were included in the final analysis. All available inpatient and outpatient clinical records were reviewed. Data relevant to diagnostic studies, treatment modalities, follow-up, recurrence, and clinical outcome measures were collected. Spetzler-Martin grade was calculated based on radiological reports of nidus size, drainage, and location. Modified Rankin Scale (mRS) scores were determined from provider documentation at presentation and at each follow-up encounter. The followup protocol at this institution included an intraoperative or immediately postoperative angiogram, followed by annual MRI and angiography at 5 and 10 years. Patient follow-up in this cohort in some cases varied due to other unforeseen issues related to scheduling, insurance status, and decisions made by providers other than the primary surgeon. For these reasons, patients were followed with a combination of CT angiography (CTA), MRI, and in some cases, MR angiography (MRI/MRA) and/or DSA at varying time points.
results
Twenty-four girls and 21 boys with a mean age of 11.7 years (range 0.5-18 years) were diagnosed with AVMs during the study period. The most common presenting finding was intracranial hemorrhage (66.7%). The most common presenting symptoms were headache (55.6%) and weakness (28.9%). Supratentorial lesions comprised 97.8% of the group. Patients were treated with microsurgical resection (15.6%), embolization alone (15.6%), radiosurgery alone (4.4%), embolization and microsurgical resection (42.2%), or embolization and radiosurgery (4.4%). Seven patients (15.6%) received no treatment, while one patient's treatment status was unavailable (2.2%; Table 1 ). Posttreatment DSA confirmed total obliteration of the nidus in 27 of the 45 patients, of whom 20 had more than 1 year of followup. This subset of 20 patients was used for all subsequent analysis. The mean follow-up duration was 5.75 years (median 5.53 years, range 1.11-10.64 years). The characteristics of this group were similar to those of the overall cohort with the exception of treatment strategy, which included a higher percentage of patients undergoing craniotomy. Spetzler-Martin Grade II and III lesions comprised 64.5% of the entire cohort, and 70% of the completely treated patients (p = 0.37, Table 1 ). Patients in the completely treated group had a higher preoperative mRS score than those excluded from the study. On follow-up assessment, however, there was no difference between the groups (Table 2) .
Surveillance for recurrence in patients with complete nidus obliteration after treatment consisted of CTA, MRI/ MRA, DSA, or a combination of these imaging modalities as dictated by the provider and described above. In addition to the intraoperative or immediate postoperative imaging study confirming no residual lesion, 2 patients (10%) had follow-up DSA, 5 (25%) had DSA and MRI/ MRA, 9 (45%) had MRI/MRA only, 1 (5%) had CTA only, and 3 (15%) had no imaging within the first 3 years of follow-up. At 5 years posttreatment, 2 patients (10%) were followed with MRI/MRA only, 2 (10%) with DSA only, and 10 (50%) with continued DSA and MRI/MRA (Table 3) . Of the follow-up MRI/MRA studies, 6 were Gdenhanced MRI only, while the remaining 7 were a combination of Gd-enhanced MRI and unenhanced 3D timeof-flight MRA.
Recurrence was observed in 3 (15%) of 20 patients aged 7-18 years (Fig. 1) . The median time to recurrence was 33.6 months (mean 41.5 months, range 19-71 months). Recurrences were identified in 2 cases by surveillance DSA, and in the third following rehemorrhage (Table 4) . Two recurrences were identified after previously normal MRI/MRA (interval of 6 months and 2 years, respectively). One of the 3 patients with recurrence had a negative digital subtraction angiogram more than 1 year postoperatively, 2 years prior to the study demonstrating recurrence. No other associated risk factors for recurrence-including emergent treatment (p = 0.52), pretreatment hemorrhage (p = 0.99), Spetzler-Martin grade (p = 0.99), AVM size (p = 0.99) and drainage (p = 0.54), and associated aneurysms (p = 0.99)-were found to correlate with recurrence in this study, and no recurrences were diagnosed by other imaging modalities.
illustrative cases of recurrent avms case 1
This 6-year-old girl presented with headache, vomiting, and seizure, at which time a Spetzler-Martin Grade II right parietal AVM with posterior middle cerebral artery feeders and a draining vein into the transverse sinus was diagnosed using DSA. She required external ventricular drain (EVD) placement and underwent embolization followed by craniotomy for resection. Intraoperative DSA demonstrated no residual AVM filling. She recovered well and underwent DSA 18 months later, revealing a recurrent AVM in the right lateral ventricle with feeders from the right anterior choroidal artery (AChA). The family declined treatment, and she continues under observation. 17 (85) 11 (55) 8 (40) 6 (30) 6 (30) 2 (10) 1 (5) 1 (5) 13 (52) 14 (56) 5 (20) 6 (24) 5 (20) 2 (8) 1 (4) 2 (8) 0 case 2 A 14-year-old girl presented with right hemiparesis and altered mental status and was found to have an ICH requiring placement of an EVD. She underwent DSA, which demonstrated a Spetzler-Martin Grade IV left thalamic AVM. The AVM was supplied by the left AChA, posterior choroidal, and posterior cerebral artery feeders, and drained into the left internal cerebral vein. She underwent 50% embolization followed by stereotactic radiosurgery. Follow-up MRI/MRA was unrevealing at 18 months, and DSA at 20 months demonstrated resolution of the AVM. Follow-up MRI/MRA 3.5 years after treatment was stable, and she presented with a new left thalamic hemorrhage 6 months later. Angiography at that time revealed a recurrent AVM in the left thalamus, which was treated with stereotactic radiosurgery.
case 3
An 8-year-old girl presented with left hemiplegia and underwent emergency evacuation of a right frontoparietal ICH. Subsequent DSA demonstrated a Spetzler-Martin Grade II AVM with right pericallosal artery feeders and deep drainage. She underwent preoperative embolization followed by craniotomy and resection of the AVM. Postoperative DSA showed no residual filling, and MRI/MRA was completed annually at 2, 3, and 4 years. At 6 years, DSA demonstrated a small local recurrence. This nidus was embolized and completely resected without complication.
discussion
Arteriovenous malformations of the brain may develop as early as the third week of gestation but typically remain asymptomatic until late adolescence or early adulthood. 2, 8, 19 Only 18%-20% of patients with AVMs present before 15 years of age, 13, 17 with hemorrhage and seizure being the most common primary events. 1, 5, 31, 32 Treatment of AVMs includes microsurgical resection, radiosurgery, endovascular embolization, or a combination of these strategies. 3, 6, 24, 28 Accumulating evidence has demonstrated that AVMs recur in children. 1, 2, 14, 16 The rate of hemorrhage associated with recurrent AVMs is not well defined, largely due to relatively small numbers of patients available for study. We confirm in our series that recurrences do occur in the pediatric population, and demonstrate that they can present with hemorrhage despite recent negative imaging. This raises an important question: what is the best modality for surveillance of these children?
Lang et al. presented a cohort in which patients who underwent postoperative DSA at 1 year demonstrated a recurrence rate of zero, while 4 patients who had a postoperative study at an earlier time point presented within 5 years with recurrence. 16 This finding lends support to the concept that delayed postoperative DSA is needed to monitor for recurrent AVM in children. However, it should be noted that long-term follow-up in our series identified 1 patient with a recurrence 6 years after complete resection with a previously negative surveillance DSA at 4 years (Case 3), as illustrated in Fig. 2 . Others have reported recurrence occurring as late as 16 years after initial treat- (15) 1 (5) 2 (10) 12 (60) 2 (10) 11 (55) 1 (5) 3 (15) 3 (15) 2 (10) 2 (10) 1 (5) 10 ( ment. 29 We affirm that delayed DSA is needed, and contend that repeated studies are essential to diagnose recurrent AVM before catastrophic hemorrhage.
Our findings confirm that long-term follow-up in children is a requirement after AVM treatment. 1, 6, 20 We find, consistent with previous reports, that MRI/MRA as performed in this cohort was unhelpful for the detection of subtle recurrence. 1 Furthermore, subjecting young children to MRI is often not a trivial matter, frequently requiring conscious sedation or general anesthesia to achieve adequate imaging. In our series, 1 patient was found to have a recurrence on DSA after negative MRI and MRA, while another presented with hemorrhage from a recurrent AVM after negative MRI and MRA. The third patient was found to have a recurrent lesion on DSA after an earlier negative DSA. With this knowledge, and the fact that more than one-third of patients were followed with MRI and/or MRA alone in the first 3 years of follow-up and some indefinitely, we postulate that recurrence rates may be even higher than we observed in our cohort.
While our data did not support the value of Gd-enhanced MRI or 3D time of flight MRA in surveillance of fully treated AVMs in children, we must acknowledge that the combination of sequences used over the 14 years of this study does not represent the most sensitive MRI available today. New techniques employing 3-T magnets and the latest 3D contrast-enhanced time-resolved MRA, also known as 4D MRA, are emerging for imaging AVMs. However, the most recent evidence on the subject still demonstrates that DSA is substantially more sensitive in surveillance and detection, although these new modalities do have a role in grading and treatment planning for known lesions. 21, 25 As we observe in Fig. 1 , AVM recurrence in our cohort was at times a very subtle finding, reinforcing the idea that noninvasive modalities for follow-up that are currently available may not be sufficient to detect it.
The appropriate follow-up imaging protocol in children with treated AVMs has not been established, although most recommend DSA as a component of the follow-up paradigm. 1, 9, 16 Concern regarding the safety of radiation exposure in children has caused a shift away from studies involving the use of ionizing radiation, such as angiography and CT. 7, 22 Recent estimates have placed the mean radiation dose to the skin from a single diagnostic angiogram in a child under the age of 21 at 239.4 mGy, while the dose absorbed by the brain is lower. Infants experience a slightly higher dose due to skull thickness, but the total is still less than 1 Gy. 22 White et al. demonstrated that in children undergoing surveillance for shunt malfunction, the mean brain dose from a mean of 16.3 CT scans in the first year of life was 321 mGy, with no increase in the risk of malignancy over the 10-21 years of follow-up. 30 Consistent with this conclusion, the largest study of population-based risk of malignancy after radiation exposure by dose demonstrated no significant increase in the relative risk of malignancy after exposure to 0.01-9.99 Gy. 27 Additionally, neurological and nonneurological risks of DSA in the infant population were recently reviewed at our institution with no increase in morbidity in this population. 11 All of this accumulating evidence suggests that the additional risk of favoring DSA over MRI/MRA in a follow-up protocol after AVM treatment is minimal, and unlikely to surpass the risk of hemorrhage from an undetected recurrence.
We propose an approach in which each patient is evaluated with an intraoperative or early postoperative angiogram to confirm complete resection, followed by a repeat angiographic study at 1 year to confirm the absence of a nidus. After that time, follow-up DSA would be performed at 3 years, which would coincide with the median time to recurrence in our study. Subsequent DSA would be performed again at 5 and 10 years and every 5 years subsequently. The combination of our experience with that of other investigators suggests that this strategy would capture most pediatric recurrences without subjecting children to annual or more frequent invasive vascular studies utilizing ionizing radiation and general anesthesia. 1, 16 As one of our recurrences occurred after a negative DSA, it is also possible that DSA will incompletely diagnose recurrence. Based on our findings, however, the addition of MRI/MRA to the follow-up paradigm is unlikely to increase the sensitivity of diagnosis or prevent symptomatic recurrence between imaging intervals. While a noninvasive study that does not employ ionizing radiation is an attractive alternative to parents and providers, our data call into question the role of MRI/MRA in surveillance after treatment of pediatric AVM. This study is limited by a small sample size with few recurrences, consistent with the low overall incidence of AVM hemorrhage in the general pediatric population. As with any retrospective analysis, we are limited by potential bias of treating providers and our data collection. Further, our sample contains few patients with CTA follow-up only, leaving room for further study regarding the validity of CTA as a substitute for DSA in our proposed treatment paradigm. As the quality and sensitivity of CTA or 4D enhanced MRA-generated images improves, one may consider replacement of DSA at interval time points, but this approach will require additional validation.
conclusions
Our experience supports the fact that conventional angiography is currently a more sensitive modality for detecting recurrent AVMs than MRI/MRA. Given the apparent lack of benefit attained from MRI/MRA accompanied by the challenges of achieving high-quality results in young children, we conclude that there is little added value to combining MRA with DSA in a postoperative follow-up paradigm. We suggest a surveillance strategy that utilizes DSA at defined intervals so as to maximize the sensitivity of follow-up studies while sparing the child exposure to excessive ionizing radiation, anesthesia, and the risks of conventional angiography.
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